GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medtronic, Inc. (MDT) [hlAlert]

Rating:
Equal Weight
MDT
up 95.58 %

Medtronic, Inc. (MDT) rated Equal Weight with price target $41 by Barclays Capital

Posted on: Friday,  Jan 6, 2012  12:25 PM ET by Barclays Capital

Barclays Capital rated Equal Weight Medtronic, Inc. (NYSE: MDT) on 01/06/2012. Previously Barclays Capital rated Overweight Medtronic, Inc. (NYSE: MDT) on
01/18/2011., when the stock price was $37.59. Since then, Medtronic, Inc. has gained 95.58% as of 08/27/2015's recent price of $73.52.
If you would have followed the previous Barclays Capital's recommendation on MDT, you would have gained 95.58% of your investment in 1682 days.

Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The primary markets for products are the United States, Western Europe and Japan. In July 2008, it acquired Restore Medical, Inc. In November 2008, Medtronic acquired CryoCath Technologies Inc. In February 2009, it acquired Ablation Frontiers, Inc. and Ventor Technologies Ltd. In April 2009, Medtronic acquired CoreValve, Inc.

Barclays Capital has assembled a world-class, award-winning team of analysts covering, credit, commodities, economics, emerging markets, equities, fixed income, foreign exchange and market strategy. We provide in-depth analysis of companies and macro coverage across asset classes, markets and the world’s economies. We have a highly quantitative approach and our research is underpinned by sophisticated analytics. Combined, these provide clients with the tools and insights necessary for successful risk management and financing. Our research teams are based in many of the world’s major financial centres providing our clients with a globally integrated perspective across products and geographies.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/6/2012 12:25 PM Buy
None
38.88 41.00
as of 12/31/2012
1 Week down  -1.63 %
1 Month down  -2.58 %
3 Months down  -4.87 %
1 YTD up  7.24 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/23/2011 12:25 PM Buy
None
39.47 46.00
1/18/2011 1:25 PM Buy
None
37.59 43.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy